文献速递乳腺癌

monarchE研究长期患者报告结局:阿贝西利联合内分泌治疗用于HR+、HER2-、淋巴结阳性、高危早期乳腺癌辅助治疗

Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer.
PubMed 文献 · Eur J Cancer · 2024-01-16

monarchE研究中,阿贝西利在42个月中位随访时显示持续的无浸润性疾病生存获益且安全性可耐受。本研究报道全部患者停用阿贝西利后,2年治疗期及随访期间的患者报告结局更新。结果显示,除腹泻外,两组生活质量各量表及单项均值变化相似,组内和组间均低于预设阈值;阿贝西利组腹泻在3个月和6个月时出现有意义差异。结论认为阿贝西利毒性可耐受且可逆,联合内分泌治疗未损害生活质量。

要点

  • 两组生活质量各量表均值变化相似,均低于预设阈值。
  • 除腹泻外,所有单项均值变化组内和组间相似。
  • 阿贝西利组腹泻在3个月和6个月时有意义差异(5分制分别增加1.19和1.03分)。

核心结论

  • 患者报告结局证实阿贝西利毒性可耐受且可逆,联合内分泌治疗未损害生活质量,支持其用于HR+、HER2-、高危早期乳腺癌患者。

研究设计与样本

  • monarchE研究,患者于基线、治疗期间3、6、12、18、24个月及停药后1、6、12个月完成FACT-B、FACT-ES和FACIT-Fatigue量表。
  • 采用混合效应重复测量模型估计组内和组间生活质量量表及单项相对基线的变化,预设有意义变化阈值,未进行统计学检验。
  • 基线时患者报告结局工具完成率>96%。

主要发现

  • 所有生活质量量表均值相对基线的变化在组内和组间数值相似(即低于预设阈值)。
  • 除腹泻外,所有单项均值变化组内和组间相似。
  • 阿贝西利组内,腹泻在3个月和6个月时观察到有意义差异(5分制均值分别增加1.19和1.03分)。
  • 治疗期间两组多数患者(69-78%)对副作用感到「有一点」或「完全无」困扰。
  • 两组疲劳模式总体相似;治疗后随访期间两组患者报告结局与基线相似。

局限性

  • 未进行统计学检验,有意义变化为预设阈值。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In monarchE, abemaciclib demonstrated a sustained benefit in invasive disease-free survival and a tolerable safety profile at 42-months median follow-up. With no expected disease-related symptoms, therapies in the adjuvant setting should preserve quality of life (QoL). With all patients off abemaciclib, we report updated patient-reported outcomes (PROs) for the full 2-year treatment period and follow-up. METHODS: Patients completed PROs including FACT-B, FACT-ES, and FACIT-Fatigue at baseline, 3, 6, 12, 18, and 24 months during treatment, and 1, 6, and 12 months after treatment discontinuation. Mixed effects repeated measures model estimated changes from baseline within and between arms for QoL scales and individual items. Meaningful changes were prespecified and no statistical testing was performed. Frequencies of responses to items associated with relevant adverse events and treatment bother were summarized. RESULTS: At baseline, completion rates for PRO instruments were >96 %. Mean changes from baseline for all QoL scales were numerically similar within and between arms (ie, less than prespecified thresholds). The same was observed for all individual items, except diarrhea. Within abemaciclib arm, meaningful differences for diarrhea were observed at 3 and 6 months (mean increases of 1.19 and 1.03 points on 5-point scale, respectively). During treatment, most patients in both arms (69-78 %) reported being bothered "a little bit" or "not at all" by side effects. Overall, patterns for fatigue were similar between arms. During post-treatment follow-up, PROs in both arms were similar to baseline. CONCLUSION: PRO findings confirm a tolerable and reversible toxicity profile for abemaciclib. QoL was preserved with the addition of adjuvant abemaciclib to endocrine therapy, supporting its use in patients with HR+, HER2-, high-risk early breast cancer.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Tolaney SM, Guarneri V, Seo JH, et al. Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer. Eur J Cancer. 2024. PMID: 38244363. doi:10.1016/j.ejca.2024.113555

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。